Chinese patients with essential hypertension were treated with the β-blocker metoprolol and followed up for 12 weeks. xTAG® liquid-chip technology was used for CYP2D6 100 C > T and ADRB1 1165G > C genotyping.
This study provides the first evidence to support that ADRB1 polymorphisms play an important role in the DBPs response to carvedilol treatment in patients with essential hypertension.
The one reported here is a prospective, observational, clinical study in Chinese Han hypertensive patients on the combined influences of CYP2D6 and beta(1) adrenoreceptor polymorphisms on the therapeutic effects of metoprolol in 300 out-patients with essential hypertension.
Our goal was to determine whether the polymorphisms rs1801253" genes_norm="153">Arg389Gly (rs1801253) and rs1801252" genes_norm="153">Ser49Gly (rs1801252) of the ADRB1 gene were associated with essential hypertension in Chinese.
Thus, the aim of the present study was to investigate the association between beta(1)-adrenoceptor gene polymorphisms and essential hypertension in a south Indian Tamil population.3.
Our findings show that the Arg389Gly polymorphism of the ADRB1 gene confers higher risk of left ventricular hypertrophy in human essential hypertension.
beta(1)-Adrenergic receptor genotype was determined by polymerase chain reaction-restriction fragment length polymorphism assay for 223 patients with essential hypertension.
One hundred and two patients with essential hypertension and left ventricular hypertrophy were allocated randomly to groups to receive double-blind treatment with either irbesartan (n = 49) or the beta(1)-adrenergic receptor blocker, atenolol ( n= 53).